Galectin Therapeutics announced NAVIGATE trial results on belapectin for MASH cirrhosis will be presented at MASH-TAG Conference.
Quiver AI Summary
Galectin Therapeutics, Inc. announced that it will present top-line results from the NAVIGATE trial regarding its drug belapectin for patients with MASH cirrhosis and portal hypertension at the 2025 MASH-TAG Conference in Park City, Utah, from January 9-11, 2025. The presentation will highlight how belapectin, administered at a specific dosage over 18 months, reduced the development of varices in these patients. Additionally, the company's leadership will conduct one-on-one meetings during the JP Morgan Healthcare Conference in San Francisco from January 13-16, 2025, to discuss the NAVIGATE trial results and future steps for the belapectin program, which has received Fast Track designation from the FDA for its potential to address chronic liver disease and cancer.
Potential Positives
- Top-line results from the NAVIGATE trial will be presented at a significant industry conference, highlighting Galectin Therapeutics' commitment to advancing their research and gaining visibility in the market.
- The drug belapectin has received Fast Track designation from the FDA, signaling its potential importance in addressing a pressing medical need associated with liver diseases.
- The company is actively engaging with external stakeholders at upcoming conferences, indicating a proactive approach to partnership and collaboration for further development of their therapies.
Potential Negatives
- The press release highlights a reliance on external partnerships for the advancement of clinical programs, indicating potential vulnerability in their development strategy.
- The announcement of trial results may imply unmet expectations or past concerns regarding the efficacy of belapectin, necessitating further discussions with stakeholders.
- The focus on presenting results at the MASH-TAG Conference, rather than achieving significant breakthroughs, suggests the company may still be in the early stages of validating their product’s effectiveness in the market.
FAQ
What are the NAVIGATE trial results being presented at MASH-TAG Conference?
The NAVIGATE trial results demonstrate that belapectin reduced varices development in MASH cirrhosis patients.
When will the NAVIGATE trial results be presented?
The results will be presented on January 10, 2025, at 11:25 AM MST during the conference.
Who is presenting the NAVIGATE trial results?
Naim Alkhouri, M.D., Chief Medical Officer of Arizona Liver Health, will present the trial results.
What is belapectin and its significance?
Belapectin is a galectin-3 inhibitor aimed at treating chronic liver disease and has received Fast Track designation by the FDA.
Where can I find more information about Galectin Therapeutics?
Additional information is available at www.galectintherapeutics.com, which details their therapies and developments.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$GALT Insider Trading Activity
$GALT insiders have traded $GALT stock on the open market 14 times in the past 6 months. Of those trades, 11 have been purchases and 3 have been sales.
Here’s a breakdown of recent trading of $GALT stock by insiders over the last 6 months:
- HAROLD H. SHLEVIN purchased 6,500 shares.
- KARY ELDRED has traded it 2 times. They made 2 purchases, buying 13,969 shares and 0 sales.
- KEVIN D FREEMAN has traded it 4 times. They made 4 purchases, buying 21,300 shares and 0 sales.
- RICHARD A. JR. ZORDANI has traded it 4 times. They made 4 purchases, buying 13,500 shares and 0 sales.
- KHURRAM JAMIL (Chief Medical Officer) sold 13,654 shares.
- JOEL LEWIS (President and CEO) sold 56,000 shares.
- JACK W CALLICUTT (Chief Financial Officer) sold 40,000 shares.
To track insider transactions, check out Quiver Quantitative's insider trading dashboard.
$GALT Hedge Fund Activity
We have seen 33 institutional investors add shares of $GALT stock to their portfolio, and 22 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- SOLTIS INVESTMENT ADVISORS LLC added 140,750 shares (+inf%) to their portfolio in Q3 2024
- SUSQUEHANNA INTERNATIONAL GROUP, LLP removed 120,868 shares (-59.7%) from their portfolio in Q3 2024
- NORTHERN TRUST CORP added 107,306 shares (+84.5%) to their portfolio in Q3 2024
- SQUAREPOINT OPS LLC removed 56,639 shares (-67.4%) from their portfolio in Q3 2024
- OSAIC HOLDINGS, INC. added 56,100 shares (+5.0%) to their portfolio in Q3 2024
- MAN GROUP PLC removed 53,045 shares (-80.7%) from their portfolio in Q3 2024
- BLACKROCK, INC. added 43,341 shares (+2.8%) to their portfolio in Q3 2024
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
Full Release
NORCROSS, Ga., Jan. 10, 2025 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today announced that the top-line results of the NAVIGATE trial in patients with MASH cirrhosis and portal hypertension will be presented during the 2025 MASH-TAG Conference, being held January 9-11, 2025 in Park City, Utah. Additionally, Company’s executive leadership will be hosting one-on-one meetings in San Franscico January 13-16, 2025, during JP Morgan Healthcare Conference and is looking forward to engaging external stakeholders on NAVIGATE topline results and discussing next steps for the belapectin program.
Presentation details
Title:
Belapectin administered at 2mg/kg/LBW for 18 months reduced the incidence of varices development in patients with MASH cirrhosis and portal hypertension: Top line results from the NAVIGATE trial
Presenter:
Naim Alkhouri, M.D., Chief Medical Officer, Arizona Liver Health, Chandler, AZ
Format:
Oral presentation
Session:
Deep Dive into Incretin and Endocrine Based Therapies
Date & Time:
January 10, 2025 at 11:25 AM MST
About Galectin Therapeutics
Galectin Therapeutics is dedicated to developing novel therapies to improve the lives of patients with chronic liver disease and cancer. Galectin’s lead drug belapectin is a carbohydrate-based drug that inhibits the galectin-3 protein, which is directly involved in multiple inflammatory, fibrotic, and malignant diseases, for which it has Fast Track designation by the U.S. Food and Drug Administration. The lead development program is in metabolic dysfunction-associated steatohepatitis (MASH, formerly known as nonalcoholic steatohepatitis, or NASH) with cirrhosis, the most advanced form of MASH-related fibrosis. Liver cirrhosis is one of the most pressing medical needs and a significant drug development opportunity. Additional development programs are in treatment of combination immunotherapy for advanced head and neck cancers and other malignancies. Advancement of these additional clinical programs is largely dependent on finding a suitable partner. Galectin seeks to leverage extensive scientific and development expertise as well as established relationships with external sources to achieve cost-effective and efficient development. Additional information is available at
www.galectintherapeutics.com
.
Company Contact:
Jack Callicutt, Chief Financial Officer
(678) 620-3186
[email protected]
Investors Relations Contacts:
Kevin Gardner
[email protected]
Chris Calabrese
[email protected]
Galectin Therapeutics and its associated logo is a registered trademark of Galectin Therapeutics Inc. Belapectin is the USAN assigned name for Galectin Therapeutics’ galectin-3 inhibitor belapectin.
